- Home
- UTHR vs TPR Comparison
UTHR vs TPR Comparison
Compare UTHR & TPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- TPR
- Stock Information
- Founded
- UTHR 1996
- TPR 1941
- Country
- UTHR United States
- TPR United States
- Employees
- UTHR N/A
- TPR N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- TPR Apparel
- Sector
- UTHR Health Care
- TPR Consumer Discretionary
- Exchange
- UTHR Nasdaq
- TPR Nasdaq
- Market Cap
- UTHR 20.7B
- TPR 20.7B
- IPO Year
- UTHR 1999
- TPR 2000
- Fundamental
- Price
- UTHR $453.53
- TPR $111.37
- Analyst Decision
- UTHR Buy
- TPR Buy
- Analyst Count
- UTHR 14
- TPR 18
- Target Price
- UTHR $471.50
- TPR $112.89
- AVG Volume (30 Days)
- UTHR 658.6K
- TPR 2.1M
- Earning Date
- UTHR 10-29-2025
- TPR 11-06-2025
- Dividend Yield
- UTHR N/A
- TPR 1.42%
- EPS Growth
- UTHR 16.08
- TPR N/A
- EPS
- UTHR 26.38
- TPR 0.82
- Revenue
- UTHR $3,128,400,000.00
- TPR $7,010,700,000.00
- Revenue This Year
- UTHR $13.82
- TPR $4.04
- Revenue Next Year
- UTHR $5.71
- TPR $4.41
- P/E Ratio
- UTHR $17.26
- TPR $137.71
- Revenue Growth
- UTHR 13.50
- TPR 5.09
- 52 Week Low
- UTHR $266.98
- TPR $46.77
- 52 Week High
- UTHR $479.50
- TPR $118.56
- Technical
- Relative Strength Index (RSI)
- UTHR 62.66
- TPR 43.72
- Support Level
- UTHR $409.15
- TPR $115.10
- Resistance Level
- UTHR $479.50
- TPR $116.38
- Average True Range (ATR)
- UTHR 13.12
- TPR 2.84
- MACD
- UTHR -1.19
- TPR -0.82
- Stochastic Oscillator
- UTHR 57.20
- TPR 2.98
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About TPR Tapestry Inc.
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.